Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.

Journal of clinical lipidology - 1 Jan 2000

Chapman M John, Orsoni Alexina, Robillard Paul, Therond Patrice, Giral Philippe

Abstract excerpt

BACKGROUND: Statins impact the metabolism, concentrations, composition, and function of circulating lipoproteins. OBJECTIVE: We evaluated time course relationships between statin-mediated reduction in atherogenic apolipoprotein B (ApoB)-containing particles and dynamic intravascular remodeling of ApoAI-containing lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol Ester Transfer Proteins
Share to Dyslipidemias

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Lipoproteins

Share to Metabolic Syndrome

Share to Phenotype

Share to Time Factors

Share to Treatment Outcome

Source

Identifiers

PMID: 29574070
DOI: 10.1016/j.jacl.2018.02.001

Genes

CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.PMID 29574070Read ↗

The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.Semantic proximity Read ↗

The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?Semantic proximity Read ↗

Metabolic origins and clinical significance of LDL heterogeneity.Semantic proximity Read ↗

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.Semantic proximity Read ↗

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.Semantic proximity Read ↗

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.Semantic proximity Read ↗

Multidimensional lipid phenotyping for stratification of residual cardiovascular risk: A focus on fatty acid balance.Semantic proximity Read ↗

Lipoprotein Signatures of Cholesteryl Ester Transfer Protein and HMG-CoA Reductase InhibitionSemantic proximity Read ↗

Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects.Semantic proximity Read ↗

Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study.Semantic proximity Read ↗

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.Semantic proximity Read ↗

LDL size: does it matter?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.